CG Oncology
CGON
96 hedge funds and large institutions have $1.7B invested in CG Oncology in 2024 Q1 according to their latest regulatory filings, with 96 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
88.84% more ownership
Funds ownership: 0% → 88.84% (+89%)
45% less call options, than puts
Call options by funds: $48K | Put options by funds: $88K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DC
Decheng Capital
Menlo Park,
California
|
+$223M |
| 2 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$146M |
| 3 |
BlackRock
New York
|
+$103M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$90.9M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
+$77M |
Top Sellers
CGON Hedge Fund Activity: Q1 2024 in Review
96 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in CG Oncology (CGON) for Q1 2024, worth a combined $1.7B.
Buyers outnumbered sellers: 96 funds opened new CGON positions and 0 closed out — a net gain of 96 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Decheng Capital, opening a new position worth an estimated $223M.
- 96 institutional investors held CG Oncology (CGON) as of Q1 2024, up from 0 in Q4 2023.
- Funds reported $1.7B of CG Oncology stock for Q1 2024.
- 96 funds opened new CG Oncology positions in Q1 2024 and 0 closed out, a net change of +96 holders.
- The largest CG Oncology buyer in Q1 2024 was Decheng Capital, an estimated $223M added.
Based on aggregated 13F filings for Q1 2024.